Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
DOI:
https://doi.org/10.2340/1651-226X.2024.20337Keywords:
prostate cancer, abiraterone, enzalutamide, cardiovascular adverse events, androgen deprivation therapy, hormone therapyAbstract
Background and purpose: There is growing concern about the adverse metabolic and cardiovascular effects of abiraterone acetate (AA) and enzalutamide (ENZ), two standard hormonal therapies for prostate cancer. We analysed the risk of cardiovascular adverse events among patients treated with AA and ENZ.
Patients and methods: We used Kythera Medicare data from January 2019 to June 2023 to identify patients with at least one pharmacy claim for AA or ENZ. The index date was the first prescription claim date. Patients were required to have 1 year of data pre- and post-index date. New users excluded those with prior AA or ENZ claims and pre-existing cardiovascular comorbidities. Demographic and clinical variables, including age, socioeconomic status (SES), comorbidity score, prostate-specific comorbidities, and healthcare costs, were analysed . Propensity score matching was employed for risk adjustment.
Results: Of the 8,929 and 8,624 patients in the AA and ENZ cohorts, respectively, 7,647 were matched after adjusting for age, sociodemographic, and clinical factors. Between the matched cohorts (15.54% vs. 14.83%, p < 0.05), there were no statistically significant differences in any cardiovascular event after adjusting for these factors. The most common cardiovascular event in both cohorts was heart failure (5.20% vs. 4.49%), followed by atrial fibrillation (4.42% vs. 3.60%) and hypotension (2.93% vs. 2.48%).
Interpretation: This study provides real-world evidence of the cardiovascular risk of AA and ENZ that may not appear in clinical trial settings. Adjusting for age, baseline comorbidities, and SES, the likelihood of a cardiovascular event did not differ between treatment groups.
Downloads
References
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89.
https://doi.org/10.14740/wjon1191 DOI: https://doi.org/10.14740/wjon1191
Hung A, Candelieri D, Li Y, et al. Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer. Semin Oncol. 2023;50(1–2):11–24.
https://doi.org/10.1053/j.seminoncol.2023.03.001 DOI: https://doi.org/10.1053/j.seminoncol.2023.03.001
Zhang W, Wu T-Y, Chen Q, et al. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review. Asian J Androl. 2017;19(2):196.
https://doi.org/10.4103/1008-682X.178483 DOI: https://doi.org/10.4103/1008-682X.178483
Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2023: 1–7 https://doi.org/10.1038/s41391-023-00725-8 DOI: https://doi.org/10.1038/s41391-023-00725-8
Halwani AS, Rasmussen KM, Patil V, et al., editors. Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol Semin Original Investig. 2020; 38(1):1.e1–1.e10.
https://doi.org/10.1016/j.urolonc.2019.09.027 DOI: https://doi.org/10.1016/j.urolonc.2019.09.027
George DJ, Sartor O, Miller K, et al. Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourinary Cancer. 2020;18(4):284–94.
https://doi.org/10.1016/j.clgc.2019.12.019 DOI: https://doi.org/10.1016/j.clgc.2019.12.019
Serrano Domingo JJ, Alonso Gordoa T, Lorca Álvaro J, et al. The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Therap Adv Urol. 2021;13:17562872211043341.
https://doi.org/10.1177/17562872211043341 DOI: https://doi.org/10.1177/17562872211043341
Recine F, Sternberg CN. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol. 2015;4(3):355–64.
https://doi.org/10.3978/j.issn.2223-4683.2015.04.11
American Urological Association. Advanced prostate cancer: AUA/SUO guideline 2023 [Internet]. [cited 15-12-2023]. Available from: https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer
Shah YB, Shaver AL, Beiriger J, et al. Outcomes following abiraterone versus enzalutamide for prostate cancer: a scoping review. Cancers (Basel). 2022;14(15):3773.
https://doi.org/10.3390/cancers14153773 DOI: https://doi.org/10.3390/cancers14153773
Ingrosso G, Detti B, Scartoni D, et al., editors. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018;45(5–6):303–15.
https://doi.org/10.1053/j.seminoncol.2018.10.001 DOI: https://doi.org/10.1053/j.seminoncol.2018.10.001
Kakarla M, Ausaja Gambo M, Yousri Salama M, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer patients: a systematic review. Cureus. 2022;14(6):e26209.
https://doi.org/10.7759/cureus.26209 DOI: https://doi.org/10.7759/cureus.26209
Ye Y, Zheng Y, Miao Q, Ruan H, Zhang X. Causes of death among prostate cancer patients gaed 40 years and older in the United States. Front Oncol. 2022;12:914875.
https://doi.org/10.3389/fonc.2022.914875 DOI: https://doi.org/10.3389/fonc.2022.914875
Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580–7.
https://doi.org/10.1200/JOP.18.00178 DOI: https://doi.org/10.1200/JOP.18.00178
Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourinary Cancer. 2018;16(3):e645–53.
https://doi.org/10.1016/j.clgc.2017.12.007 DOI: https://doi.org/10.1016/j.clgc.2017.12.007
Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world sata. Clin Genitourin Cancer. 2022;20(1):17–24.
https://doi.org/10.1016/j.clgc.2021.08.009 DOI: https://doi.org/10.1016/j.clgc.2021.08.009
Schoen MW, Carson KR, Eisen SA, et al. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis. 2023;26(4):743–50.
https://doi.org/10.1038/s41391-022-00588-5 DOI: https://doi.org/10.1038/s41391-022-00588-5
Baser O, Samayoa G, Yapar N, Baser E, Mete F. Use of open claims vs closed claims in health outcomes research. J Health Econ Outcomes Res. 2023;10(2):44–52.
https://doi.org/10.36469/jheor.2023.87538 DOI: https://doi.org/10.36469/jheor.2023.87538
United States Census Bureau [Internet]. [9-12-2023]. Available from: https://www.census.gov/.
United States Census Bureau. Selected housing characteristics [Internet]. [9-12-2023]. Available from: https://data.census.gov/table?q=housing+value&g=010XX00US,$8600000&tid=ACSDP5Y2021.DP04
United States Census Bureau. Interest, dividends, or net rental income in the past 12 months for households [Internet]. [9-12-2023]. Available from: https://data.census.gov/table?q=interest,+dividend,+or+rental+income+in+household&g=010XX00US,$8600000&tid=ACSDT5Y2021.B19054
United States Census Bureau. Selected population profile in the United States [Internet]. [9-12-2023]. Available from: https://data.census.gov/table?q=occupations+&t=Educational+Attainment&g=010XX00US,$8600000&tid=ACSSPP1Y2021.S0201
Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188–97.
Putnam KG, Buist DS, Fishman P, et al. Chronic disease score as a predictor of hospitalization. Epidemiology. 2002;13(3):340346.
https://doi.org/10.1097/00001648-200205000-00016 DOI: https://doi.org/10.1097/00001648-200205000-00016
Mehta HB, Sura SD, Adhikari D, et al. Adapting the Elixhauser comorbidity index for cancer patients. Cancer. 2018;124(9):2018–25.
https://doi.org/10.1002/cncr.31269 DOI: https://doi.org/10.1002/cncr.31269
Baser O, Palmer L, Stephenson J. The estimation power of alternative comorbidity indices. Value Health. 2008;11(5):946–55. Epub 20080516. doi: 10.1111/j.1524-4733.2008.00343.x. PubMed PMID: 18489502. DOI: https://doi.org/10.1111/j.1524-4733.2008.00343.x
Ng HS, Koczwara B, Roder D, Vitry A. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Prostate Cancer Prostatic Dis. 2018;21(3):403–10.
https://doi.org/10.1038/s41391-018-0036-y DOI: https://doi.org/10.1038/s41391-018-0036-y
Henríquez I, Roach M 3rd, Morgan TM, et al. Current and emerging therapies for metastatic castration-resistant prostate cancer (mCRPC). Biomedicines. 2021;9(9):1247.
https://doi.org/10.3390/biomedicines9091247 DOI: https://doi.org/10.3390/biomedicines9091247
Fradin J, Kim FJ, Lu-Yao GL, Storozynsky E, Kelly WK. Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer. Cancers (Basel). 2023;15(8).
https://doi.org/10.3390/cancers15082316 DOI: https://doi.org/10.3390/cancers15082316
Cao B, Kim M, Reizine NM, Moreira DM. Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis. Eur Urol Oncol. 2023;6(3):237–50.
https://doi.org/10.1016/j.euo.2023.01.001 DOI: https://doi.org/10.1016/j.euo.2023.01.001
Conover MM, Weaver J, Fan B, et al. Cardiovascular outcomes among patients with castration-resistant prostate cancer: a comparative safety study using US administrative claims data. Prostate. 2023;83(7):729–39.
https://doi.org/10.1002/pros.24510 DOI: https://doi.org/10.1002/pros.24510
Jefferson M, Drake RR, Lilly M, Savage SJ, Tucker Price S, Hughes Halbert C. Co-morbidities in a retrospective cohort of prostate cancer patients. Ethn Dis. 2020;30(Suppl 1):185–92.
https://doi.org/10.18865/ed.30.S1.185 DOI: https://doi.org/10.18865/ed.30.S1.185
Su YL, Chou CL, Rau KM, Lee CT. Asthma and risk of prostate cancer: a population-based case-cohort Study in Taiwan. Medicine (Baltimore). 2015;94(36):e1371.
https://doi.org/10.1097/MD.0000000000001371 DOI: https://doi.org/10.1097/MD.0000000000001371
Chhatre S, Gallo JJ, Guzzo T, et al. Trajectory of depression among prostate cancer patients: a secondary analysis of a randomized controlled trial. Cancers (Basel). 2023;15(7).
https://doi.org/10.3390/cancers15072124 DOI: https://doi.org/10.3390/cancers15072124
Cone EB, Reese S, Marchese M, et al. Cardiovascular toxicities associated with abiraterone compared to enzalutamide – a pharmacovigilance study. EClinicalMedicine. 2021;36:100887.
https://doi.org/10.1016/j.eclinm.2021.100887 DOI: https://doi.org/10.1016/j.eclinm.2021.100887
Scailteux LM, Despas F, Balusson F, et al. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients. Br J Clin Pharmacol. 2022;88(1):336–46.
https://doi.org/10.1111/bcp.14972 DOI: https://doi.org/10.1111/bcp.14972
Lee HY, Chen HL, Teoh JY, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2021;24(1):244–52.
https://doi.org/10.1038/s41391-020-00275-3 DOI: https://doi.org/10.1038/s41391-020-00275-3
Sidelnikov E, Dornstauder E, Jacob C, et al. Healthcare resource utilization and costs of cardiovascular events in patients with atherosclerotic cardiovascular disease in Germany – results of a claims database study. J Med Econ. 2022;25(1):1199–206.
https://doi.org/10.1080/13696998.2022.2141964 DOI: https://doi.org/10.1080/13696998.2022.2141964
Alexander MR. 2022 [Internet] [21-12-2023]. Available from: https://emedicine.medscape.com/article/241381-overview#:~:text=and%20endocrine%20causes.-,Primary%20or%20essential%20hypertension%20accounts%20for%2090%2D95%25%20of%20adult,inadequate%20medication%20or%20poor%20compliance
Bishesh Shrestha SGaASN. Cardiovascular adverse events associated with androgen receptor-targeted therapy used in the treatment of prostate cancer. Circulation. 2020;142:A16180.
https://doi.org/10.1161/circ.142.suppl_3.16180 DOI: https://doi.org/10.1161/circ.142.suppl_3.16180
Levine GN, D’Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121(6):833–40.
https://doi.org/10.1161/CIRCULATIONAHA.109.192695 DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192695
O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51.
https://doi.org/10.1200/JCO.2014.59.1792 DOI: https://doi.org/10.1200/JCO.2014.59.1792
Ryan C, Wefel JS, Morgans AK. A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer Prostatic Dis. 2020;23(2):207–19. DOI: https://doi.org/10.1038/s41391-019-0195-5
Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA. Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. Am Health Drug Benefits. 2017;10(3):143–53.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Onur Baser, Gabriela Samayoa, Archana Dwivedi, Sara AlSaleh, Burhan Cigdem, Erdi Kizilkaya
This work is licensed under a Creative Commons Attribution 4.0 International License.
